MedTrace Logo

21-day Double-blind Trial of Albendazole in Adults With Loa Loa Microfilaremia

NCT06613997 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-09-26

No results posted yet for this study

Summary

Our aim is to test the hypothesis that a 3-week course of albendazole 400 mg daily is safe and can progressively reduce Loa loa microfilarial densities in subjects with microfilaremia.

Conditions

  • Loiasis With Positive Blood Microfilaremia
  • Loiasis

Interventions

DRUG

Albendazole 400mg

Albendazole 400mg per days for 21 consecutive days

DRUG

Placebo

Placebo for 21 consecutive days

Sponsors & Collaborators

  • Institut de Recherche pour le Developpement

    collaborator OTHER_GOV

  • Programme National de Lutte contre l'Onchocercose, Republic of the Congo

    lead OTHER_GOV

Principal Investigators

  • Jéremy CAMPILLO, PharmD PhD · Institut de Recherche pour le Développement (IRD)

  • François MISSAMOU, MD · Programme National de Lutte contre l'Onchocercose (PNLO)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-15
Primary Completion
2026-12-31
Completion
2027-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06613997 on ClinicalTrials.gov